Close

Disclosure of Information

The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and Information Related to Human Gene Therapy or Xenotransplantation." 66 Fed. Reg. 4688 (January 18, 2001) (the Proposed Rule or FDA’s Proposal).

TESTIMONY OF THOMAS OKARMA, MD, PhD PRESIDENT AND CEO OF GERON CORPORATION ON BEHALF OF THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS COMMITTEE ON ENERGY AND COMMERCE US HOUSE OF REPRESENTATIV

by Thomas Okarma, CEO, Geron, subcommittee on Oversight and Investigations

Letter to President George Bush Regarding Cloning

Letter to President George W. Bush

BIO Position on Stem Cell Research

As expressed in a joint letter to President-Elect Bush.

Recombinant DNA Research

Recombinant DNA Research, Proposed Actions Under the NIH Guidelines.

Testimony on the Proposed Rule on Confidentiality of Patient Records

Regarding the Proposed Rule on Confidentiality of Patient Records Could Impede Research before the Senate Health, Education, Labor and Pensions Committee.

Testimony of Michael J. Werner, Esq.

On behalf of the Biotechnology Industry Organization (BIO), regarding the Proposal That Calls For A Moratorium on Some Human Gene Therapy Protocols before the NIH Recombinant DNA Advisory Committee.

Comments on Proposed Standards for Privacy of Individually Identifiable Health Information

Addressed to Margaret Ann Hamburg, M.D., Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services.

Testimony of H. Stewart Parker

On behalf of the Biotechnology Industry Organization (BIO), on oversight of gene therapy before the U.S. Senate Health, Education, Labor and Pensions Subcommittee on Public Health.

Comments submitted to Secretary's Advisory Committee on Genetic Testing in response to the public consultation

On Genetic Testing in response to the public consultation.